Division of Clinical Pharmacology

Study finds certain genetic test not useful in predicting heart disease risk

A Polygenic Risk Score — a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients — has been found not to be a useful predictive biomarker for disease risk.

Interim directors of Cardiovascular Medicine named

Dan Roden, MD, and Daniel Munoz, have been named interim directors of the Division of Cardiovascular Medicine at Vanderbilt University Medical Center.

Roden wins Schottenstein Prize from Ohio State University

Researchers on the NCI Moonshot grant focused on hereditary cancers include (front row, from left) Natasha Celaya-Cobbs, LPN, Georgia Wiesner, MD, Sarah Bland, MPH, MBA, (back row, from left) Trent Rosenbloom, MD, Josh Peterson, MD, MPH, and Marc Beller, PMP, BA.

NCI ‘Moonshot’ grant to boost hereditary cancer identification

VUMC is leading an initiative to establish a streamlined process for collection of family health histories that could set the stage for a standardized system to make the information easily accessible.

Article examines need for genotyping after stenting

Genotyping can improve outcomes in patients who require anti-platelet therapy following stent placement to open narrowed or blocked coronary arteries and prevent a heart attack.

Peterson, Roden honored for translational medicine efforts

Josh Peterson, MD, MPH, and Dan Roden, MD, are among 10 leaders in clinical pharmacology and translational medicine recognized this week by the American Society for Clinical Pharmacology and Therapeutics.

1 3 4 5 6 7 11